title: PTK7 expression in triple-negative breast cancer.
abstract: BACKGROUND
  Protein tyrosine kinase-7 (PTK7) plays an important role in cancer. Our aim was to evaluate PTK7 in triple-negative breast cancer (TNBC).
  
  
  METHODS
  PTK7 Expression was assessed by immunohistochemistry (IHC) in 133 patients with TNBC. Expression levels were correlated with clinicopathological features and survival, taking chemotherapy into account.
  
  
  RESULTS
  Positive PTK7 expression was detected in 28.6% of tumors. In the total population, no significant difference was detected in disease-free survival (DFS) or overall survival (OS) related to PTK7 status. However, in patients treated by chemotherapy, patients with PTK7-negative tumors seemed to have better DFS than those with PTK7-positive tumors, particularly for patients treated with only anthracycline-therapy drugs. In patients receiving other chemotherapy regimens, PTK7 status had no significant impact on DFS or OS.
  
  
  CONCLUSIONS
  Our results support earlier findings that PTK7 may be associated with resistance to anthracycline-based chemotherapy.
authors.affiliation: Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Henricistrasse 92, 45136 Essen, Germany. ataseven@gmx.net.
authors.forename: Beyhan
authors.initials: B
authors.lastname: Ataseven
authors.forename: Regina
authors.initials: R
authors.lastname: Angerer
authors.forename: Ronald
authors.initials: R
authors.lastname: Kates
authors.forename: Angela
authors.initials: A
authors.lastname: Gunesch
authors.forename: Pjotr
authors.initials: P
authors.lastname: Knyazev
authors.forename: Bernhard
authors.initials: B
authors.lastname: Högel
authors.forename: Clemens
authors.initials: C
authors.lastname: Becker
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Eiermann
authors.forename: Nadia
authors.initials: N
authors.lastname: Harbeck
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies
chemical_list: D015815:Cell Adhesion Molecules; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C096905:PTK7 protein, human
keywords: PTK7; anthracycline resistance; prognosis; triple-negative breast cancer